Welcome!

News Feed Item

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256135/Lower-Limb-Muscle-Spasticity-Global-Clinical-Trials-Review-H2-2014.html

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Lower Limb Muscle Spasticity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lower Limb Muscle Spasticity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lower Limb Muscle Spasticity. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Lower Limb Muscle Spasticity 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials by E7 Countries: Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in E7 Countries 17
Clinical Trials in E7 Countries by Trial Status 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20

Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Lower Limb Muscle Spasticity Therapeutics Clinical Trials 26
Prominent Drugs 27
Clinical Trial Profiles 28
Clinical Trial Overview of Top Companies 28
Merz Pharma GmbH & Co. KgaA 28
Clinical Trial Overview of Merz Pharma GmbH & Co. KgaA 28
Ipsen S.A. 29
Clinical Trial Overview of Ipsen S.A. 29
Allergan, Inc. 30
Clinical Trial Overview of Allergan, Inc. 30
GlaxoSmithKline plc 31
Clinical Trial Overview of GlaxoSmithKline plc 31
Clinical Trial Overview of Top Institutes / Government 32
The University of Tokushima 32
Clinical Trial Overview of The University of Tokushima 32

Tehran University of Medical Sciences 33
Clinical Trial Overview of Tehran University of Medical Sciences 33
Danish Pain Research Center 34
Clinical Trial Overview of Danish Pain Research Center 34
Assistance Publique Hopitaux De Marseille 35
Clinical Trial Overview of Assistance Publique Hopitaux De Marseille 35
Five Key Clinical Profiles 36
Appendix 112
Abbreviations 112
Definitions 112
Research Methodology 113
Secondary Research 113
About GlobalData 114
Contact Us 114
Disclaimer 114
Source 114

List of Tables

Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Region, 2014* 6
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 9
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 12

Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 13
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Lower Limb Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 18
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Phase, 2014* 19
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 20
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23

Lower Limb Muscle Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 24
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Merz Pharma GmbH & Co. KgaA, 2014* 28
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Ipsen S.A., 2014* 29
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2014* 30
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 31
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Tokushima, 2014* 32
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 33
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Danish Pain Research Center, 2014* 34
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique Hopitaux De Marseille, 2014* 35

List of Figures

Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 9
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 12
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Lower Limb Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17

Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 18
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Phase (%), 2014* 19
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 20
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Lower Limb Muscle Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 24
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
GlobalData Methodology 113

To order this report: Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256135/Lower-Limb-Muscle-Spasticity-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his session at 21st Cloud Expo, James Henry, Co-CEO/CTO of Calgary Scientific Inc., introduced you to the challenges, solutions and benefits of training AI systems to solve visual problems with an emphasis on improving AIs with continuous training in the field. He explored applications in several industries and discussed technologies that allow the deployment of advanced visualization solutions to the cloud.
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
One of the biggest challenges with adopting a DevOps mentality is: new applications are easily adapted to cloud-native, microservice-based, or containerized architectures - they can be built for them - but old applications need complex refactoring. On the other hand, these new technologies can require relearning or adapting new, oftentimes more complex, methodologies and tools to be ready for production. In his general session at @DevOpsSummit at 20th Cloud Expo, Chris Brown, Solutions Marketi...
At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
I think DevOps is now a rambunctious teenager - it's starting to get a mind of its own, wanting to get its own things but it still needs some adult supervision," explained Thomas Hooker, VP of marketing at CollabNet, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
"MobiDev is a software development company and we do complex, custom software development for everybody from entrepreneurs to large enterprises," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...
"We work around really protecting the confidentiality of information, and by doing so we've developed implementations of encryption through a patented process that is known as superencipherment," explained Richard Blech, CEO of Secure Channels Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Major trends and emerging technologies – from virtual reality and IoT, to Big Data and algorithms – are helping organizations innovate in the digital era. However, to create real business value, IT must think beyond the ‘what’ of digital transformation to the ‘how’ to harness emerging trends, innovation and disruption. Architecture is the key that underpins and ties all these efforts together. In the digital age, it’s important to invest in architecture, extend the enterprise footprint to the cl...
Leading companies, from the Global Fortune 500 to the smallest companies, are adopting hybrid cloud as the path to business advantage. Hybrid cloud depends on cloud services and on-premises infrastructure working in unison. Successful implementations require new levels of data mobility, enabled by an automated and seamless flow across on-premises and cloud resources. In his general session at 21st Cloud Expo, Greg Tevis, an IBM Storage Software Technical Strategist and Customer Solution Architec...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
"We were founded in 2003 and the way we were founded was about good backup and good disaster recovery for our clients, and for the last 20 years we've been pretty consistent with that," noted Marc Malafronte, Territory Manager at StorageCraft, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Effectively SMBs and government programs must address compounded regulatory compliance requirements. The most recent are Controlled Unclassified Information and the EU's GDPR have Board Level implications. Managing sensitive data protection will likely result in acquisition criteria, demonstration requests and new requirements. Developers, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by incorporating changes. In...